ArticleFrontiers in oncology2025
High BMI-attributable female-specific cancers: a comprehensive analysis of the global disease burden and trends from 1990 to 2021 and projections to 2040.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High body mass index (BMI) is a key modifiable risk factor for breast, ovarian, and uterine cancer. Despite the ongoing global obesity epidemic, a systematic assessment of the long-term burden trends and disparities of these cancers attributable to high BMI is lacking, particularly across regions with different sociodemographic development. This study quantifies these trends and disparities, providing an evidence base to inform equitable global cancer prevention strategies. Methods: We extracted data on deaths and disability-adjusted life years (DALYs) for breast, ovarian, and uterine cancer attributable to high BMI from 1990 to 2021 across 204 countries from the Global Burden of Disease 2021 study. We used Joinpoint regression to analyze temporal trends in age-standardized rates (ASRs), employed efficiency frontier analysis to assess burden control, and quantified inequalities using the Slope Index of Inequality (SII) and Concentration Index (CI). Finally, an Autoregressive Integrated Moving Average (ARIMA) model was used to project burden trends to 2040. Results: Globally, from 1990 to 2021, annual deaths attributable to high BMI for these cancers more than doubled from 36,000 to 88,000, while DALYs rose from 0.83 million to 2.13 million. Burden trajectories showed marked divergence by Sociodemographic Index (SDI). In high-SDI regions, the burdens of breast and ovarian cancer declined, while the uterine cancer burden increased (AAPC in ASDALYs = 0.86%). Conversely, in low- and middle-SDI regions, the burdens of three cancers increased. The most pronounced rise occurred in ovarian cancer in low-SDI regions (ASDR AAPC of 4.49%). Inequality analysis revealed a widening absolute gap in burden, with the SII for ovarian cancer increasing by 95.3%. Projections indicate that DALY burdens for breast and ovarian cancer will continue to increase by 2040. Conclusion: The rising global burden of female-specific cancers attributable to high BMI is shifting disproportionately to low-SDI regions, exacerbating absolute health inequalities. This highlights an urgent need to integrate weight management and nutritional interventions into equitable, context-specific prevention strategies to address this growing global health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.